角质细胞分化因子1通过激活PI3K/AKT通路来增强宫癌细胞的活力和迁移
Chao Chen1, Junhua Liao2, Xingxing Sun1
1Department of Obstetrics and Gynecology, Wujin Hospital Affiliated with Jiangsu University, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, China.
概括
细胞分化因子1 (KDF1) 在宫癌中表达高,促进细胞活力和迁移. 准KDF1和PI3K/AKT通路可能为宫癌治疗提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 宫癌是全球重要的健康问题.
- 了解推动子宫癌进展的分子机制对于开发有效的治疗方法至关重要.
- 角质细胞分化因子1 (KDF1) 已涉及到各种细胞过程.
研究的目的:
- 研究KDF1在宫癌中的作用.
- 阐明KDF1影响子宫癌细胞的潜在分子机制.
- 评估KDF1作为宫癌的潜在治疗标.
主要方法:
- 基因表达特征交互分析 (GEPIA) 数据库被用于分析KDF1的表达.
- 在HeLa宫癌细胞中建立了KDF1过度表达和淘汰模型.
- 使用定量实时PCR,西式涂抹,CCK-8,Transwell和伤口愈合分析.
- 使用PI3K抑制剂 (LY294002) 评估了酸3-激酶 (PI3K) /蛋白激酶B (AKT) 途径.
主要成果:
- 在宫癌组织和细胞系中,KDF1表达显著上调,与预后不佳相关.
- 抑制KDF1降低了宫癌细胞的增殖,迁移和入侵,并降低了PI3K/AKT通路的激活.
- 过度表达KDF1增强了恶性行为,并激活了PI3K/AKT通路,PI3K抑制剂的作用部分逆转.
结论:
- 通过激活PI3K/AKT通路,KDF1通过增强细胞活力和迁移来促进宫癌的进展.
- KDF1代表了宫癌治疗的潜在治疗标.
- 针对KDF1和PI3K/AKT信号通路可能为宫癌患者提供新的治疗策略.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:35Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:07MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K